Scientific Publications by FDA Staff

Pharm Stat 2016 Jul;15(4):349-61

Testing treatment effect in schizophrenia clinical trials with heavy patient dropout using latent class growth mixture models.

Kong F, Chen YF

By examining the outcome trajectories of the dropout patients with different reasons in the schizophrenia trials, we note that although patients are recruited from the same protocol that have compatible baseline characteristics, they may respond differently even to the same treatment. Some patients show consistent improvement while others only have temporary relief. This creates different patient subpopulations characterized by their response and dropout patterns. At the same time, those who continue to improve seem to be more likely to complete the study while those who only experience temporary relief have a higher chance to drop out. Such phenomenon appears to be quite general in schizophrenia clinical trials. This simultaneous inhomogeneity both in patient response as well as dropout patterns creates a scenario of missing not at random and therefore results in biases when we use the statistical methods based on the missing at random assumption to test treatment efficacy. In this paper, we propose to use the latent class growth mixture model, which is a special case of the latent mixture model, to conduct the statistical analyses in such situation. This model allows us to take the inhomogeneity among subpopulations into consideration to make more accurate inferences on the treatment effect at any visit time. Comparing with the conventional statistical methods such as mixed-effects model for repeated measures, we demonstrate through simulations that the proposed latent mixture model approach gives better control on the Type I error rate in testing treatment effect.